Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 27Observational 2Expanded_access 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Recurrence 2Multiple Myeloma 2

Interventions

elotuzumab 4Bortezomib 4Lenalidomide 3Dexamethasone 3talquetamab 2selinexor 2pomalidomide 2carfilzomib 2Panobinostat 2venetoclax 1ulocuplumab 1plerixafor 1idecabtagene vicleucel 1fludarabine phosphate 1daratumumab 1ceritinib 1belantamab mafodotin 1Whole-Body Irradiation 1Tacrolimus 1Prednisone 1Mycophenolic Acid 1Melphalan 1Cytarabine 1Crizotinib 1Cord Blood Stem Cell Transplantation 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × talquetamab × Plasma cell × Clear all
NCT05503550 2025-12-16

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

No longer available
Plasma cell

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Approved for marketing
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡